12 years of revenue, profit, cash flow and balance-sheet history through FY2025,
from SEC filings — with a computed, factual read of the trend.
Updated Overview →
Growth & profitability
Revenue has declined 2.0% per year over the past 5 years.
Operating margin has expanded, at 0.2% in the latest year.
Financial health
The company is unprofitable; at its current free-cash-flow burn it has roughly 1.2 years of cash runway.
Revenue & net income
RevenueNet income
Margins (gross / operating / net)
GrossOperatingNet
Free cash flow (CFO − capex)
Free cash flow
Cash vs total debt
CashTotal debt
Cash flow: operating / investing / financing
OperatingInvestingFinancing
Key annual figures
FY
Revenue
Net income
Gross M
Op M
FCF
Total debt
Cash
2025
$160M
-$811000
0.0%
0.2%
-$4M
—
$6M
2024
$185M
-$811000
0.0%
1.1%
-$7M
—
$10M
2023
$191M
-$30M
0.0%
1.8%
$8M
—
$18M
2022
$206M
-$2M
0.0%
7.3%
$23M
$0
$10M
2021
$195M
$15M
0.0%
3.9%
-$5M
$5M
$12M
2020
$177M
-$2M
0.0%
-6.0%
-$11M
$27M
$29M
2019
$218M
-$26M
0.0%
-9.9%
$9M
$19M
$28M
2018
$285M
$18M
0.0%
-9.1%
-$13M
$14M
$21M
2017
$384M
-$42M
0.0%
-10.6%
-$36M
$0
$8M
2011
—
$44M
—
—
$40M
$179M
$86M
2010
—
$54M
—
—
$79M
$193M
$85M
2009
—
$48M
—
—
$105M
—
$87M
Revenue & net income
RevenueNet income
Margins (gross / operating / net)
GrossOperatingNet
Free cash flow (CFO − capex, quarterly)
Free cash flow
Cash vs total debt
CashTotal debt
Cash flow: operating / investing / financing
OperatingInvestingFinancing
Key quarterly figures
Quarter
Revenue
Net income
Gross M
Op M
FCF
Total debt
Cash
Mar '26
$37M
-$628000
0.0%
-2.1%
-$922000
—
$5M
Dec '25
$40M
$2M
0.0%
-0.3%
-$686000
—
$6M
Sep '25
$40M
-$2M
0.0%
1.3%
$2M
—
$7M
Jun '25
$39M
-$335000
0.0%
0.1%
-$5M
—
$5M
Mar '25
$42M
-$392000
0.0%
-0.1%
-$923000
—
$9M
Dec '24
$47M
-$2M
0.0%
-3.3%
$3M
—
$10M
Sep '24
$48M
$142000
0.0%
4.0%
-$5M
—
$6M
Jun '24
$45M
-$28M
0.0%
3.0%
$926000
—
$11M
Mar '24
$45M
-$171000
0.0%
0.8%
-$6M
—
$11M
Dec '23
$49M
-$2M
0.0%
-4.6%
$3M
—
$18M
Sep '23
$47M
$618000
0.0%
6.2%
$1M
—
$13M
Jun '23
$48M
$580000
0.0%
3.5%
$2M
—
$13M
Mar '23
$47M
-$791000
0.0%
2.2%
$1M
—
$13M
Dec '22
$55M
$22M
0.0%
6.3%
$6M
$0
$10M
Sep '22
$54M
$7M
0.0%
7.0%
$10M
$0
$7M
Jun '22
$49M
$4M
0.0%
8.3%
$8M
$10M
$11M
Mar '22
$49M
$3M
0.0%
7.9%
-$2M
$5M
$10M
Dec '21
$52M
$2M
0.0%
5.5%
$4M
$5M
$12M
Sep '21
$50M
$4M
0.0%
8.5%
-$3M
$13M
$16M
Jun '21
$49M
$11M
0.0%
2.9%
$712000
$13M
$12M
Valuation over time
How the market has priced HHS against its own fundamentals since 2023-03 —
each month-end's share price set against the most recent annual filing, so the multiple moves
as price runs ahead of (or behind) earnings. Split-adjusted.
The price-to-sales ratio has fallen from 0.3× (Mar '23) to 0.1× (Jun '26).
Price / sales (P/S)
P/S
Frequently asked questions
Is HHS growing its revenue and profit?
Over the past 5 years, HARTE HANKS INC's revenue has declined 2.0% per year. These are computed facts, not advice.
How much debt does HHS have?
As of FY2025, HARTE HANKS INC reported — of total debt against $6M of cash.
What is HHS's profit margin?
In FY2025, gross margin was —, operating margin 0.2%, and net margin -0.5%.
Where does this data come from?
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted ·
growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price
against the latest annual filing. Informational only — not investment advice.